Timing of #Remdesivir Initiation and Clinical #Outcomes in Hospitalized Patients with #COVID19 Who Are at High Risk of Disease Progression in #Japan: A Health Insurance Claims Database Study

#Remdesivir as a potent #antiviral against prototype and current #epidemic #Oropouche virus #strains (BeAn19991 and PE-IAM4637)

Molecular basis of #SARS-CoV-2 proofreading enzyme–mediated #resistance to #remdesivir

#Remdesivir: Effectiveness and Safety in Hospitalized #COVID19 #Patients—Analysis of Retrospectively Collected Data from Daily Practice in #Omicron Variant Era and Comparison with the Pre-Omicron Period

#SARS-CoV-2 #Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug #Resistance

Delays in COVID antiviral receipt raised risk of poor outcomes after ED visits by 18%, data suggest

#Remdesivir, mAb114, REGN-EB3, and #ZMapp partially rescue nonhuman #primates infected with a low passage #Kikwit variant of #Ebola virus

#Remdesivir and #Obeldesivir Retain Potent #Antiviral Activity Against #SARS-CoV-2 #Omicron Variants

The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.

The use of fixed dose-combinations of antivirals with different mechanisms of action has proven key in the successful treatment of infections with HIV…